Citigroup’s Krystal Biotech KRYS Stock Holding History

Citigroup’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200	Closed	-$35.3K	–	6274
2025 Q3	$35.3K	Sell	200 -17,800	-99%	-$2.66M	﹤0.01%	4602
2025 Q2	$2.47M	Hold	18,000	–	–	﹤0.01%	2452
2025 Q1	$3.25M	Sell	18,000 -2,000	-10%	-$336K	﹤0.01%	2293
2024 Q4	$3.13M	Buy	+20,000	New	+$3.55M	﹤0.01%	2429
2023 Q4	–	Sell	-12,400	Closed	-$1.44M	–	5789
2023 Q3	$1.44M	Buy	+12,400	New	+$1.51M	﹤0.01%	2237
2023 Q2	–	Sell	-8,300	Closed	-$664K	–	5654
2023 Q1	$664K	Buy	+8,300	New	+$652K	﹤0.01%	2891

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's KRYS Position: Q1 2026 in Review

Citigroup increased its Krystal Biotech (KRYS) stake by 4.1% in Q1 2026, buying an estimated $327K and bringing the position to 31,172 shares worth $8.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

Citigroup first reported a position in KRYS in Q4 2018 and has held it in 30 quarters since. The position peaked at $15.6M in Q4 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Citigroup held 31,172 shares of Krystal Biotech worth $8.05M as of Q1 2026.
Citigroup bought 1,229 Krystal Biotech shares in Q1 2026, an estimated $327K.
Krystal Biotech made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1607 holding.
Citigroup first reported a position in Krystal Biotech in Q4 2018 and has held it in 30 quarters since.
Citigroup's Krystal Biotech position peaked at $15.6M in Q4 2024.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.